Single User
£3750
PDF
44 pages

Fragile X Syndrome Forecast in 11 Major Markets 2016-2026


Fragile X syndrome (FXS) is an X-linked dominant genetic disorder. It is caused by a defect in the fragile-X mental retardation 1 gene (FRM1); this defect prevents the FRM1 gene from expressing FMRP. The FMRP protein, most commonly found in the brain, is essential for normal cognitive development and female reproductive function. FXS is the leading genetically inherited cause of intellectual and developmental disability.

This report provides the current prevalent population for Fragile X Syndrome across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Australia, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fragile-X have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Features associated with Fragile X Syndrome include:

  • Autistic-like features
  • Fragile X tremor ataxia syndrome (FXTAS)
  • Fragile X primary ovarian insufficiency (FXPOI)
  • Attention problems
  • Anxiety
  • Hyperactivity

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in the global Fragile X Syndrome market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Fragile X Syndrome and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various
  • Provide a level of understanding on the impact from specific co-morbid conditions on Fragile X Syndrome’s prevalent population.
  • Identify sub-populations within Fragile-x which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Fragile-x patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Fragile X Syndrome
  • Features of Fragile X Syndrome Patients
    • Severity
    • IQ Score
    • Autistic-like features
    • Fragile X Tremor Ataxia Syndrome (FXTAS)
    • Fragile X Primary Ovarian Insufficiency (FXPOI)
    • Attention Problems
    • Anxiety
    • Hyperactivity
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
    List of Tables
  • Prevalence of Fragile X Syndrome, total (000s)
  • Prevalence of Fragile X Syndrome, males (000s)
  • Prevalence of Fragile X Syndrome, females (000s)
  • Fragile X Syndrome patients by Severity, total (000s)
  • Fragile X Syndrome patients by IQ Score, total (000s)
  • Autistic-like features in Fragile X Syndrome patients, total (000s)
  • FXTAS in Fragile X Syndrome patients, total (000s)
  • FXPOI in Fragile X Syndrome patients, total (000s)
  • Attention problems in Fragile X Syndrome patients, total (000s)
  • Anxiety in Fragile X Syndrome patients, total (000s)
  • Hyperactivity in Fragile X Syndrome patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • USA Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • France Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • France Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • Germany Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • Germany Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • Italy Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • Italy Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • Spain Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • Spain Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • UK Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • UK Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • Australia Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • Australia Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • Japan Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • Japan Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • India Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • India Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
  • China Prevalence of Fragile X Syndrome by 5-yr age cohort, males (000s)
  • China Prevalence of Fragile X Syndrome by 5-yr age cohort, females (000s)
Australia, Brazil, China, France, Germany, India, Italy, Japan, Spain, United Kingdom